This website will close on 30 April 2024. After this date, your content will not be accessible. Please contact for more information.

Under evaluation with potential for adoption
Share innovation

MOWOOT - Intestinal Transit Management System

By Markus Wilhelms, MOWOOT Added 23rd Feb, 2020 Updated 4th May, 2020

Up to 20% of the general population are diagnosed with chronic constipation, leading to severe comorbidities and a huge impact on quality of life. Those who suffer the most are patients with neurological pathologies (80% of SCI, MS, PD) and the elderly (up to 60% in assisted living).

The economic burden on the NHS is huge: £162 million was spent by NHS England treating constipation in 2018 alone.

Current solutions are either pharmacological or invasive and have side effects and a high cost.

MOWOOT is the first non-drug, non-invasive solution to constipation adressing this huge unmet need.


MOWOOT is a novel, non-drug, non-invasive solution to constipation in the form of a CE-certified class IIa medical device. With only 10-20 minutes of daily treatment, MOWOOT generates an exo-peristaltic effect that moves the faeces and solves constipation in a natural way.

Benefits: effective bowel management (easy defecation, pain relief, reduced comorbidities, reduced drug side effects, etc) and cost savings (medicines, follow-up, nursing time, etc.)

Application areas: neurogenic bowel dysfunction (NBD), opioid-induced-constipation (OIC), idiopathic chronic constipation.

MOWOOT is clinically proven and mentioned as state-of-the-art solution in the German clinical guideline for Neurogenic-Bowel-Dysfunction in Spinal-Cord-Injury.

Related Innovations